Last reviewed · How we verify
pantoprazole infusion
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Stress ulcer prophylaxis.
At a glance
| Generic name | pantoprazole infusion |
|---|---|
| Sponsor | Kwong Wah Hospital |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Pantoprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This reduces intragastric acidity and is used to treat acid-related gastrointestinal disorders. The intravenous formulation allows for rapid acid suppression in acute clinical settings where oral administration is not feasible.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Stress ulcer prophylaxis
- Zollinger-Ellison syndrome
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Hypomagnesemia (with long-term use)
Key clinical trials
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis (EARLY_PHASE1)
- Role of Octreotide in Non Variceal Bleeding (PHASE2, PHASE3)
- Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding (PHASE4)
- The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers
- Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding (NA)
- Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (PHASE2)
- Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pantoprazole infusion CI brief — competitive landscape report
- pantoprazole infusion updates RSS · CI watch RSS
- Kwong Wah Hospital portfolio CI